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Abstract
Background: Mucositis is a toxic side effect of anti-cancer treatments and is a major focus in cancer research. Pro-
inflammatory cytokines have previously been implicated in the pathophysiology of chemotherapy-induced
gastrointestinal mucositis. However, whether they play a key role in the development of radiotherapy-induced
gastrointestinal mucositis is still unknown. Therefore, the aim of the present study was to characterise the
expression of pro-inflammatory cytokines in the gastrointestinal tract using a rat model of fractionated
radiotherapy-induced toxicity.
Methods: Thirty six female Dark Agouti rats were randomly assigned into groups and received 2.5 Gys abdominal
radiotherapy three times a week over six weeks. Real time PCR was conducted to determine the relative change in
mRNA expression of pro-inflammatory cytokines IL-1b, IL-6 and TNF in the jejunum and colon. Protein expression
of IL-1b, IL-6 and TNF in the intestinal epithelium was investigated using qualitative immunohistochemistry.
Results: Radiotherapy-induced sub-acute damage was associated with significantly upregulated IL-1b, IL-6 and TNF
mRNA levels in the jejunum and colon. The majority of pro-inflammatory cytokine protein expression in the
jejunum and colon exhibited minimal change following fractionated radiotherapy.
Conclusions: Pro-inflammatory cytokines play a key role in radiotherapy-induced gastrointestinal mucositis in the
sub-acute onset setting.
Introduction
Mucositis is a debilitating side effect of cytotoxic che-
motherapy (CT) and radiotherapy (RT). It involves
inflammation and mucosal ulceration of the alimentary
tract, resulting in symptoms including pain, abdominal
bloating, nausea, vomiting and diarrhoea [1-3]. The
effects of mucositis often limit the dose of cytotoxic
agents that can be administered and in some cases, even
prevents patients from undergoing further treatment to
control the malignancy [4].
It has been postulated that mucositis occurs in five
overlapping phases: initiation, upregulation and message
generation, signalling and amplification, ulceration and
healing [5]. Nuclear factor kappa B (NFB), cyclooxy-
genase-2 (COX-2) as well as pro-inflammatory cytokines
(in particular interleukin (IL)-1b (IL-6) and tumour
necrosis factor (TNF)) have been suggested to play a
key role in this 5 phase mucositis model [5].
Previous research has clearly shown that IL-1b,I L - 6
and TNF are upregulated in the buccal mucosa, jejunum
and colon of rats following administration of che-
motherapy [6]. Furthermore, elevated levels of IL-1b
and TNF have been detected in the buccal mucosa of
hamsters who received combined chemotherapy and
radiotherapy [7,8]. In addition, various studies have
attempted to target pro-inflammatory cytokines as a
preventive measure for intestinal mucositis [8-11]. For
example, palifermin and IL-11 have been reported to be
successful in lowering the levels of pro-inflammatory
cytokines in the development of mucositis [8-11].
Furthermore, they also attenuate mucositis in animal
models [8-12], thus supporting the current view that * Correspondence: rachel.gibson@adelaide.edu.au
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Recently, we have developed a fractionated radiother-
apy-induced mucositis model in the Dark Agouti (DA)
rat [13]. The model involves rats receiving one to six
weeks of radiotherapy. In the clinical setting, fractio-
nated radiotherapy is usually more common than a sin-
gle high dose. Thus, this model provides the ideal
opportunity to explore various avenues involved in frac-
tionated radiotherapy-induced mucositis, with rats
receiving between one and three weeks of radiotherapy
representing short-term, and those receiving between
four and six weeks representing long-term radiotherapy
in the clinical setting [13]. Damage which occurs in the
short term is an acute event, while damage in the long
term is considered sub-acute. Histological damage peaks
mid treatment and begins to subside towards the com-
pletion of radiotherapy, despite worsening clinical symp-
toms of intestinal toxicity [14]. The cause of this is
unknown but may be related to inflammatory changes.
Therefore the aim of the present study was to character-
ise the expression of pro-inflammatory cytokines in the
intestines during six weeks of fractionated radiotherapy.
We hypothesise that pro-inflammatory cytokine levels in
the jejunum and colon will be elevated following radio-
therapy and that this increase will correlate with the
increasing duration and total doses of radiotherapy.
Methods
Ethics
This study was approved by the Animal Ethics Commit-
tee of the Institute of Medical and Veterinary Sciences,
Adelaide and the University of Adelaide. Animal work
and handling were complied with the National Health
and Research Council (Australia) Code of Practice for
Animal Care in Research and Teaching (2004) [13].
Irradiation Protocol and Experimental Design
Thirty six female DA rats (150 g - 170 g) were obtained
from the University of Adelaide Breeding Facility. All
animals were maintained in an environmentally con-
trolled condition of 12-h light/12-h dark cycles and
allowed free access to food and water. Rats were ran-
domly assigned to groups based on RT dose as follows:
Control (no treatment); 7.5 Gy; 15 Gy; 22.5 Gy; 30 Gy;
37.5 Gy and 45 Gy (Table 1). Detailed radiation proce-
dures have been described previously [13]. Briefly, rats
were anaesthetised prior to receiving 2.5 Gys of radio-
therapy to the abdomen three times a week for up to
six weeks.
Tissue Collection
Rats were killed by exsanguination followed by cervical
dislocation and the entire gastrointestinal tract removed.
The small and large intestines were separated and
flushed with chilled saline to remove intestinal contents.
Sections of jejunum (collected at 33% of the length from
the pyloric sphincter) and colon (collected at 50% of the
length) were collected and either fixed in 10% neutral
buffered formalin and embedded in paraffin for histo-
pathology and immunohistochemistry or snap frozen
with liquid nitrogen and stored at -70°C for real time
PCR.
Histopathology
Routine histopathological examination using standard
haematoloxylin and eosin staining was conducted. These
methods have previously been validated and described
elsewhere [15].
RNA extractions
Total RNA was isolated and purified using the NucleoS-
pin® RNA II kit (Macherey-Nagel, Duren, Germany) fol-
lowing manufacturer’s instructions. The integrity of
RNA extracted was determined by comparing sharp 28S
and 18S rRNA bands electrophoresed on a 1.5% formal-
dehyde gel and 260/280 ratios.
Reverse Transcription
1 μg RNA was reverse transcribed to generate cDNA
using the iScript™ cDNA Synthesis Kit (Bio-Rad Labora-
tories, Hercules, CA) according to manufacturer’s
instructions. 100 ng of cDNA from each sample was
subsequently used in real time PCR.
Real Time PCR
The amplification reactions were conducted in a volume
of 10 μL containing 1× Quantitect SYBR Green master
mix (Qiagen) forward and reverse primers each at a
final concentration of 2.5 ng/μL and 100 ng cDNA. Pri-
mer sequences for IL-1b, IL-6, TNF and b-actin are sta-
ted in Table 2. Real time PCR was carried out using
Rotor-Gene 6000 real time rotary analyser (Corbett Life
Science, Sydney, Australia). Taq DNA polymerase was
Table 1 Experimental Design
Group Rat Number Treatment
Duration (Weeks)
Total Radiation
Dose (Gy)
1 n = 5 1 7.5
2n = 5 2 1 5
3 n = 5 3 22.5
4n = 5 4 3 0
5 n = 5 5 37.5
6n = 5 6 4 5
Control n = 6 6 0
Groups of rats (n = 5) were exposed to varying doses of fractionated
radiotherapy over a six week period. Control rats (n = 6) received no
fractionated radiotherapy.
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denaturing at 95°C (15 s) and annealing/extension at 60°
C (1 min). Relative quantification of mRNA expression
was performed using the Delta Delta Ct (2
-ΔΔCT) method
(also known as the comparative Ct method) as described
in Livak and Schmittgen (2001) [16], using the Rotor-
Gene software. To improve sample size the original
groups were pooled into larger short term (3 weeks or
less RT) and long term (4 weeks or greater RT) groups.
Immunohistochemistry
Four micron tissue sections were dewaxed with xylene
and rehydrated through decreasing concentrations of
alcohol. Endogenous peroxidase was blocked with 0.5%
hydrogen peroxide in methanol for 20 minutes. This
was followed by antigen retrieval in citrate buffer (pH
6.0) heated in a microwave at high power (900W) (3
min) and low power (650W) (10 min). Non-specific
binding was blocked with 50% normal goat or horse
serum in PBS (pH 7.5) (Sigma-Aldrich Inc, St. Louis,
MO) Avidin and biotin was blocked using the avidin
and biotin blocking solution (Vector Laboratories, Bur-
lingame, CA). Primary antibodies (IL-1b: Rabbit Polyclo-
nal, Santa Cruz Laboratories, 1.100 dilution; IL-6: Rabbit
Polyclonal, Santa Cruz Laboratories, 1:1000 dilution;
TNF: Goat Polyclonal antibody, Hycult Biotechnology,
1:250 dilution) were applied to sections and incubated
at 4°C overnight. Primary antibody incubations were
omitted for negative controls. Sections were incubated
in biotinylated secondary antibody followed by ultra-
streptavidin peroxidase (Signet Pathology Systems Inc.,
Dedham, MA). Antibodies were visualized with diami-
nobenzidine (DAB) (Zymed laboratories, San Francisco,
CA). Sections were counterstained with Lillie Mayer’s
haematoxylin, dehydrated, cleared in xylene, cover-
slipped and viewed using light microscopy. Staining
intensity was graded according to a previously published
and validated grading system where 0 = no staining, 1 =
weak staining, 2 = moderate staining, 3 = strong stain-
ing, 4 = very intense staining [6,13,17].
Statistical Analysis
Statistical analyses were conducted using either one-way
ANOVA followed by Tukey’s Post Hoc test, or Kruskal
Wallis test followed by Dunn’s Post Hoc test. Results
were deemed significant should p < 0.05.
Results
Histopathology
Pathological changes over time in the rat intestinal tract
caused by fractionated radiotherapy have previously
been described in detail [13]. Briefly there was no histo-
pathological change at any time point in rats that did
not receive radiotherapy. However, rats that received
radiotherapy had an increase in apoptosis in the jeju-
num and colon, as well as severe goblet cell disintegra-
tion. Furthermore, there was a significant alteration in
the height of the jejuna and colonic crypts over the
radiotherapy course [13].
Change in mRNA expression of pro-inflammatory
cytokines in the jejunum
The mRNA expression of IL-1b, and TNF in rats receiv-
ing fractionated radiotherapy did not differ significantly
f r o mt h ee x p r e s s i o ni nc o n t r o la n i m a l s .H o w e v e r ,I L - 6
mRNA levels were increased (although did not reach
significance) in rats receiving 45 Gy of RT compared
with all other doses (data not shown).
When the data was pooled, mRNA expression of IL-
1b was significantly less in the short term RT group
compared with controls (Figure 1). IL-6 mRNA levels in
the long term RT group were significantly higher than
the short term RT group (Figure 1). No significant dif-
ferences in TNF mRNA levels were observed.
Change in mRNA expression of pro-inflammatory
cytokines in the colon
The mRNA expression of IL-1b,I L - 6a n dT N Fi nr a t s
receiving fractionated radiotherapy did not differ signifi-
cantly from the expression in control animals. However,
IL-1b levels in rats receiving 37.5 Gy and 45 Gy RT
were increased (although did not reach significance)
compared to all other groups (data not shown).
When these individual groups were grouped together,
there was significantly greater IL-1b mRNA expression
in rats receiving long term radiotherapy than in rats
receiving short term radiotherapy (Figure 2). IL-6
mRNA levels of rats in the control, short term and long
term radiotherapy groups did not differ significantly
(Figure 2). Rats receiving long term radiotherapy
demonstrated a significantly higher TNF mRNA expres-
sion from rats which received short term radiotherapy
(Figure 2).
Table 2 Primer sequences for IL-1b, IL-6, TNF and b actin
Gene Primer Sequence Size
(bp)
Accession
No
IL-1b Forward: 5’-CACCTCTCAAGCAGAGCACAGA-3’ 81 NM_031512
Reverse: 5’-ACGGGTTCCATGGTGAAGTC-3’
IL-6 Forward: 5’-ATATGTTCTCAGGGAGATCTTGGAA-3’ 80 NM_031512
Reverse: 5’-GTGCATCATCGCTGTTCATACA
TNF Forward: 5’-GTGATCGGTCCCAACAAG-3’ 71 X66539
Reverse: 5’-AGGGTCTGGGCCATGGAA-3’
b actin Forward: 5’-AGGCCAACCGTGAAAAGATG-3’ 101 NM_031144
Reverse: 5’-ACCAGAGGCATACAGGGACAA-3’
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Figure 1 mRNA expression of IL-1b, IL-6 and TNF in the Jejunum of DA rats in the following groups: untreated controls, short term
course of radiotherapy (Weeks 1 - 3), long term course of radiotherapy (Weeks 4 - 6). Data are expressed as mean + SEM. There was a
significant decrease in IL-1 expression between short-term radiotherapy groups and controls (p < 0.05). There was a significant increase in IL-6
between long-term radiotherapy and short-term radiotherapy groups (p < 0.05).
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Figure 2 mRNA expression of IL-1b, IL-6 and TNF in the Colon of DA rats in the following groups: untreated controls, short term
course of radiotherapy (Weeks 1 - 3), long term course of radiotherapy (Weeks 4 - 6). Data are expressed as mean + SEM. There was a
significant increase in both IL-1b and TNF expression between short term and long term radiotherapy groups (p < 0.05).
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jejunum and colon
IL-1b
In general, there was weak-moderate IL-1b staining in
the jejunal crypts. There was predominantly weak stain-
ing of the villi. The intensity of IL-1b staining fluctuated
throughout six weeks of radiotherapy (Data not shown).
IL-1b staining intensity in the colon was weak-moderate
over six weeks of radiotherapy. Staining was variable
between the basal and apical regions of the crypts and
did not significantly change of the course of radiother-
apy (Data not shown).
IL-6
IL-6 staining was weak-moderate in the crypts of the
jejunum and weak in the villi. No differences in IL-6
expression were observed over six weeks of radiotherapy
(Data not shown). IL-6 expression in the colon did not
change over six weeks of radiotherapy. IL-6 staining
intensity in the basal region of the crypt (moderate to
strong) was slightly higher than the apical region (weak
to moderate) (data not shown).
TNF
TNF staining was moderate in the jejuna crypts. No
staining was seen along the villi. TNF protein levels did
not appear to differ among individual groups of rats
which underwent one to six weeks of radiotherapy and
controls (Figure 3). No TNF was expressed in the colon
of rats that had not received radiotherapy. TNF expres-
sion increased slightly over the course of six weeks of
radiotherapy, being particularly evident after 22.5 Gy
and 30 Gy. (Figure 4). There was more TNF staining
observed towards the basal region of the crypt.
Submucosal protein expression of IL-1b, IL-6 and TNF
All tissue sections were assessed for the submucosal
protein expression of IL-1b, IL-6 and TNF. There was
no apparent submucosal staining in the vast majority of
sections. Occasional sections had positive staining in
b l o o dv e s s e l sa n di nt h ec e l l so ft h el a m i n ap r o p r i a
(data not shown).
Discussion
This study has shown for the first time, using the frac-
tionated radiotherapy-induced mucositis rat model, that
mRNA levels of pro-inflammatory cytokines, IL-1b, IL-6
and TNF, are significantly upregulated in the intestines
following long term radiotherapy when compared to
short term radiotherapy. Significant reductions in IL-1b
mRNA levels were found in the jejunum during short
term radiotherapy. The upregulation of pro-inflamma-
tory cytokine mRNA levels was seen in rats receiving
either five or six weeks of radiotherapy, and supports
the Sonis [5] hypothesis that pro-inflammatory cytokines
increase with increasing fractionated radiotherapy.
Furthermore, the elevated levels of pro-inflammatory
cytokines following five and six weeks of radiotherapy
correlates with histological evidence of intestinal muco-
sitis and peak expression of NFB [13]. Together, these
f i n d i n g ss t r o n g l ys u g g e s tt h a tl o n gt e r mr a d i o t h e r a p yi s
capable of activating NFB, which subsequently stimu-
lates increased production of pro-inflammatory
Figure 3 Protein expression of TNF in the jejunum following six weeks of fractionated radiotherapy. A = control; B = 7.5 Gy; C = 15 Gy;
D = 22.5 Gy; E = 30 Gy; F = 37.5 Gy G = 45 Gy. There was no change in the level of expression at any time point. Staining was only observed
in the crypts, as indicated by the arrows. There was no staining seen in the villi.
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damage. This study also demonstrated decreased pro-
inflammatory cytokine levels in the intestines of rats
receiving one to three weeks, or short term radiother-
apy. Rats undergoing short term radiotherapy showed a
significant reduction in IL-1b mRNA levels and, to a
lesser extent, IL-6 and TNF, when compared to rats
receiving no radiotherapy. These observations are in
contrast with previous findings where pro-inflammatory
cytokine mRNA levels in the gastrointestinal tract were
found to be elevated five days following chemotherapy
in rats and 12 days post-radiation treatment in hamsters
[7,8]. The changes in pro-inflammatory cytokine levels
encountered in this current study may be due to the dif-
ferential effects of short term and long term courses of
radiotherapy, in which long term radiotherapy exerts
pro-inflammatory effects as observed in high dose radia-
tion while short term radiotherapy may mimic the anti-
inflammatory effects seen in low dose radiation [18].
R a d i a t i o ne x p o s u r ei nt h er a n g e1 - 2G yi sk n o w nt o
activate the growth stimulatory ERK pathway via EGFR
[19]. It has been suggested that this activation is
mediated through radiation-induced free radicals [19].
Free radicals are also strongly linked to activation of
NFB and the pro-inflammatory pathway, as well as
JNK signalling [20], indicating a balance between out-
comes which is highly dose-dependent and linked to
free-radical generation.
The paradoxical findings of this study may be best
explained by the degree of damage present in the short
and long term radiotherapy setting. Low dose radiation
is known to induce apoptosis, a process that suppresses
inflammation via signals released by engulfing
phagocytes. However, in areas of intense damage there
is often increased necrosis, whereby cells release factors
serving as potent stimuli for inflammation. Increasing
duration of radiation may have led to a depletion of
cytosolic pools of NAD and ATP in the intestinal cells,
resulting in a switch from apoptosis to necrosis [20] at
the later time points, consequently activating pro-
inflammatory cytokines as reflected in our results.
When pro-inflammatory cytokine levels were exam-
ined at the protein level, we saw no significant changes
in the intestinal epithelium of rats receiving radiother-
apy. Previous research into expression at the protein
level has shown conflicting findings. In one study, pro-
inflammatory cytokine protein levels in the epithelium
throughout the gastrointestinal tract were upregulated
as early as six hours after chemotherapy [6]. However,
another study demonstrated an increase in the protein
expression of IL-1b in the oral submucosa and not in
the epithelium following radiotherapy [8]. These discre-
pancies may be the result of different treatments. Che-
motherapy is given systemically and is generally only
administered for a single short period with the resulting,
mucosal injury usually acute [5]. Radiotherapy, on the
other hand, is a localised treatment and can cause both
acute and chronic injury [5,21]. The present study uti-
lised fractionated radiotherapy. This model is more
clinically relevant compared to other single dose radio-
therapy models as fractionated radiotherapy is more
commonly given to cancer patients. Fractionated radio-
therapy not only kills tumour cells more effectively, it
also allows normal cells to repair and regenerate in
between fractions, making them more tolerant to radia-
tion and less prone to radiation-induced damage [21].
Figure 4 Protein expression of TNF in the colon following six weeks of fractionated radiotherapy.A=c o n t r o l ;B=7 . 5G y ;C=1 5G y ;
D = 22.5 Gy; E = 30 Gy; F = 37.5 Gy G = 45 Gy. No staining was seen in the crypts of rats that had received no radiotherapy. There was an
increase in protein expression of TNF after radiotherapy, particularly after 22.5 Gy and 30 Gy as indicated by the arrow, although the staining was
not considered to be very strong.
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showed an increase in crypt length following two to six
weeks of radiotherapy [13]. This observation is exclusive
to radiotherapy as our previous studies utilising che-
motherapy have reported a reduction in crypt length
[22,23]. Therefore it is likely in this study that the crypt
cells initiated compensatory mechanisms enabling them
to repair and repopulate, resulting in increased crypt
length as well as unchanged pro-inflammatory cytokines
protein levels seen in the intestinal epithelium.
In conclusion, this novel fractionated radiotherapy-
induced mucositis model has allowed the characterisation
of pro-inflammatory cytokines IL-1b,I L - 6a n dT N Fi n
the jejunum and colon of the DA rat following radiother-
apy, thus confirming the importance of these cytokines
in the development of mucositis. Pro-inflammatory cyto-
kines were upregulated at later time points of radiother-
apy suggesting that these cytokines can ultimately induce
more tissue injury and inflammation in the intestine with
increasing total doses of radiotherapy. Expression was
altered in the epithelial compartment (not sub-epithelial
regions) indicating enterocyte upregulation rather than
infiltrating immune cells. As such, the pathophysiology of
fractionated radiotherapy-induced mucositis is different
to immune-regulated inflammatory bowel disease. How-
ever, more research is still required to clarify the localisa-
tion of these cytokines and the molecular mechanisms
involved in the development of mucositis.
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